share_log

Renal Research Institute and Karolinska Institutet Announce Chronic Kidney Disease Management Symposium, Highlighting New Therapeutics

Renal Research Institute and Karolinska Institutet Announce Chronic Kidney Disease Management Symposium, Highlighting New Therapeutics

腎臟研究所和卡羅林斯卡研究所宣佈舉辦慢性腎臟病管理研討會,重點介紹新療法
PR Newswire ·  05/18 02:38

NEW YORK, May 17, 2024 /PRNewswire/ -- Renal Research Institute (RRI), a global leader in dialysis and nephrology research and a subsidiary of Fresenius Medical Care AG, today announced together with the Karolinska Institutet a joint symposium, "Prevention of CKD progression: the impact of new therapeutics." The Karolinska Institutet is one of the world's leading medical universities.

紐約,2024年5月17日 /PRNewswire/ — 腎臟病研究領域的全球領導者、費森尤斯醫療股份公司的子公司腎臟研究所(RRI)今天宣佈與卡羅林斯卡研究所共同舉辦名爲 “預防慢性肺病進展:新療法的影響” 的聯合研討會。卡羅林斯卡學院是世界領先的醫科大學之一。

Medical experts from across the globe will discuss clinical trials, prescription practices, pharmaco-epidemiology and more at this workshop in Stockholm on May 22.

來自全球各地的醫學專家將討論臨床試驗、處方實踐、藥物流行病學等 在5月22日在斯德哥爾摩舉行的這個研討會上

With chronic kidney disease (CKD) affecting about 1 in 10 adults worldwide, new therapeutics have been developed to potentially delay its progression. Notable among these are glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i).

全球約有十分之一的成年人患有慢性腎臟病(CKD),因此已經開發出可能延緩其進展的新療法。其中值得注意的是胰高血糖素樣肽1受體激動劑(GLP-1 RA)和鈉葡萄糖共轉運蛋白2抑制劑(SGLT2i)。

"In the realm of chronic kidney disease management, GLP-1 RAs and SGLT2is have shown promising results in clinical trials," said Dr. Peter Kotanko, Head of Biomedical and Evidence Generation and Research Director, Renal Research Institute. "Our symposium aims to further advance the conversation on the potential of these new therapeutics, bringing together internationally recognized experts in diabetes, obesity, kidney and cardiovascular medicine to pave the way for improving patient care."

腎臟研究所生物醫學和證據生成負責人兼研究主任彼得·科坦科博士說:“在慢性腎臟疾病管理領域,GLP-1 RA和SGLT2I在臨床試驗中顯示出令人鼓舞的結果。”“我們的研討會旨在進一步推進關於這些新療法潛力的對話,彙集國際公認的糖尿病、肥胖、腎臟和心血管醫學專家,爲改善患者護理鋪平道路。”

The symposium aims to explore these medications and their potential impact on CKD progression in the light of the clinical trials, bringing together global medical experts and fostering an open dialogue to advance knowledge on the research through Q&A sessions, while simultaneously providing a comprehensive overview of the current landscape and future developments in the field through specialized presentations from experts.

該研討會旨在從臨床試驗的角度探討這些藥物及其對慢性腎病進展的潛在影響,彙集全球醫學專家,通過問答環節促進公開對話,增進對研究的了解,同時通過專家的專業演講,全面概述該領域的當前格局和未來發展。

To learn more about RRI educational material and events, including past symposiums, visit the RRI website at

要了解有關 RRI 教育材料和活動(包括過去的研討會)的更多信息,請訪問 RRI 網站

About Peter Kotanko, MD, FASN
Head of Biomedical Evidence Generation and Research Director, Renal Research Institute Researcher and scholar Dr. Peter Kotanko leads RRI's scientists and fellows, heading the Institute's research initiatives to improve patient outcomes and quality of life. His prolific research career comprises more than 400 research papers, book chapters, and scholarly works. With over 20 years of clinical background and expertise in physiology, internal medicine, and nephrology, Dr. Kotanko is an adjunct professor of medicine and nephrology at the Icahn School of Medicine at Mount Sinai, New York. He is former vice chair of the Department of Internal Medicine, Barmherzige Brüder Hospital in Graz, Austria.

關於 FASN 醫學博士 Peter Kotanko
生物醫學證據生成負責人和研究總監 腎臟研究所 研究員兼學者彼得·科坦科博士領導RRI的科學家和研究員,領導該研究所改善患者預後和生活質量的研究計劃。他多產的研究生涯包括 400 多篇研究論文、書籍章節和學術著作。Kotanko 博士在生理學、內科和腎臟病學方面擁有 20 多年的臨床背景和專業知識,是紐約西奈山伊坎醫學院的醫學和腎臟病學兼職教授。他曾任奧地利格拉茨巴爾赫茲格布魯德醫院內科副主任。

About Renal Research Institute (RRI)
Renal Research Institute (RRI), a subsidiary of Fresenius Medical Care, achieves its mission to improve the outcomes of patients with kidney disease through research and innovation. RRI's highly developed and specialized expertise in computational biomedicine, translational clinical and biomedical research, and data analytics underscore the Institute's track record of thinking outside the box and identifying high-value areas. Through alliance and collaboration agreements, RRI has forged strategic research relationships with leading universities in the Americas, Asia, and Europe, fostering RRI's position at the forefront of research activities in the field of dialysis and nephrology.

關於腎臟研究所(RRI)
費森尤斯醫療的子公司腎臟研究所(RRI)實現了通過研究和創新改善腎臟疾病患者預後的使命。RRI在計算生物醫學、轉化臨床和生物醫學研究以及數據分析方面高度發達的專業知識突顯了該研究所在跳出框框思維和確定高價值領域方面的往績。通過聯盟和合作協議,RRI與美洲、亞洲和歐洲的頂尖大學建立了戰略研究關係,鞏固了RRI在透析和腎臟病學領域研究活動前沿的地位。

For more information, visit the Renal Research Institute's website at .

欲了解更多信息,請訪問腎臟研究所的網站,網址爲。

About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,862 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 325,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

關於費森尤斯醫療:
費森尤斯醫療是全球領先的腎臟疾病患者產品和服務提供商,全球約有410萬患者定期接受透析治療。費森尤斯醫療通過其由3,862家透析診所組成的網絡,爲全球約32.5萬名患者提供透析治療。費森尤斯醫療還是透析機或透析器等透析產品的領先供應商。費森尤斯醫療在法蘭克福證券交易所(FME)和紐約證券交易所(FMS)上市。

Media Contact
Kirsten Stratton
T +1 781 929 8096
[email protected]

媒體聯繫人
克爾斯滕·斯特拉頓
電話 +1 781 929 8096
[電子郵件保護]

SOURCE Renal Research Institute

來源:腎臟研究所

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論